

A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb  $\geq$ 10 g/dL in response to anti-C5 antibody and switch to iptacopan

**Status:** Recruiting

## Eligibility Criteria

## Conditions & Interventions

**Keywords:**

Clinics and Surgery Center (CSC)

## More Information

**Description:** This is a multicenter, single-arm, open label trial, with iptacopan treatment for 24 weeks in adult PNH patients. Eligible participants must have a mean Hb  $\geq$ 10 g/dL in response to a stable regimen with anti-C5 for at least 6 months and must be transfusion free for the same period.

**Study Contact:** Joan Beckman - beckm092@umn.edu

**Principal Investigator:** Joan Beckman

**IRB**

**Number:** STUDY00018020

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.